Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desmopressin Sandoz is a synthetic peptide analogue of the natural pituitary hormone arginine vasopressin (antidiuretic hormone). It functions as a selective agonist for the vasopressin V2 receptors located primarily in the collecting ducts of the kidneys. By binding to these receptors, desmopressin stimulates the translocation of aquaporin-2 channels to the apical membrane, significantly increasing water permeability and reabsorption. This results in a concentrated urine and a reduction in total urine volume. Unlike natural vasopressin, desmopressin has minimal activity at V1 receptors, meaning it does not typically cause significant vasoconstriction or increase blood pressure at therapeutic doses. It is primarily indicated for the treatment of primary nocturnal enuresis (bedwetting) in children and adults, central diabetes insipidus, and nocturia in adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desmopressin sandoz.